Type 1 diabetes management requires continuous coordination of carbohydrate intake, insulin dosing, and timing, as even small mismatches can lead to significant glycemic variability. Every individual living with type 1 diabetes understands the discipline the condition demands. Even minor deviations can result in significant fluctuations in glucose levels.
Hua Tu, founder of Metabulin, explains, "scientists and clinicians have done extraordinary work advancing diabetes care under the constraints they understood. For a long time, insulin instability was treated as unavoidable. What's exciting now is that we're beginning to see that assumption may not be absolute."
This shift in perspective, according to Tu, reframes a long-standing challenge as an unexpected opportunity.
"Variability in glucose control is often framed as a failure of management," he explains. "In reality, it frequently reflects the inherent limitations of the insulin itself. We have normalized a standard of precision that is incompatible with everyday life."
In the United States alone, millions of people live with diabetes, including a substantial population with type 1 diabetes. Globally, prevalence continues to rise. While outcomes have improved over time, life expectancy for individuals with type 1 diabetes still lags behind that of the general population, underscoring the need for continued advancement in care.
While innovations in pumps, continuous glucose monitoring, and algorithm-driven dosing have significantly improved outcomes, Tu notes that they have largely focused on managing insulin's limitations rather than eliminating them. These technologies have added precision and automation, but they still operate within the biochemical constraints of the insulin molecule itself.
"The field has made remarkable progress in delivery," Tu says. "What's been less explored is whether the molecule we're delivering could be fundamentally improved. Insulin has long been considered effective when used under ideal conditions. The difficulty is that ideal conditions rarely exist, particularly for children, adolescents, and families navigating the complexities of daily life."
He emphasizes that at the center of this constraint lies a critical but underexamined issue: insulin stability. Conventional insulin formulations are sensitive to heat and mechanical stress. Under these conditions, insulin can aggregate into fibrillar structures, reducing biological activity and potentially compromising delivery performance.
Historically, Tu says, to compensate for fragility, companies have used formulations to stabilize insulin. This results in slower insulin action.#
By examining insulin at a structural level, his team focused on understanding how fibrillar aggregation occurs and how it might be prevented. "Once you understand how these fibers form, you can design around them," he explains. "We've shown that stability and speed do not need to be mutually exclusive."
The result, he adds, is a formulation designed to remain stable under stress while preserving rapid pharmacological action. According to Tu, this convergence has meaningful implications across the treatment landscape. He explains, "Greater thermal stability reduces the risk of degradation during storage and transport, particularly in regions where temperature control is inconsistent. It also enables more reliable performance under real-world conditions."
One immediate application, he notes, is insulin pump therapy. Insulin pump reservoirs are generally replaced every two to three days to ensure consistent delivery, reflecting a combination of device, physiological, and insulin stability-related limitations. "If you can move from changing a reservoir every few days to much longer intervals, that represents a meaningful shift," Tu says. "It reduces intervention and simplifies daily management."
Tu emphasizes that this has broader implications for patient experience. Fewer pump changes translate to fewer disruptions, reduced cognitive burden, and a more seamless integration of treatment into everyday life. At the same time, faster-acting insulin could better align with the body's natural metabolic response, improving postprandial glucose control and reducing the need for rigid pre-meal dosing schedules.
Tu frames this as a foundational transition in care. "We are moving toward an insulin that adapts to the patient, rather than requiring the patient to adapt to the insulin," he says. "That has the potential to redefine the standard of care."
Beyond individual benefits, he adds, this work signals a broader shift in how innovation is approached within the field. Rather than layering additional complexity onto delivery systems, according to Tu, improving the core therapeutic molecule itself may resolve many downstream challenges. Reflecting on industry trends observed at a recent American Diabetes Association conference, Tu notes a strong emphasis on delivery technologies. "It highlights a tendency to manage the consequences of instability rather than address its root cause," he says.
Importantly, he positions this advancement as a continuation of existing scientific progress rather than a correction of past efforts. "Previous work laid the foundation we are building on," he explains. "This is about extending that progress in ways that were not previously considered possible."
The implications may extend beyond diabetes. Protein instability and misfolding are challenges across multiple therapeutic areas, suggesting that the principles behind this approach could inform the design of other biologic drugs over time.
From an industry perspective, this development expands the definition of innovation. While recent progress has focused heavily on delivery systems, improving the underlying molecule introduces a new pathway for advancement. "It changes not just how we deliver insulin, but what insulin can be," Tu says. "When the core therapy improves, many downstream limitations begin to resolve."
Although Metabulin's formulation has not yet reached commercialization, Tu emphasizes that the scientific foundation is well established and advancing. The work reflects a broader reexamination of what effective diabetes care should look like in the coming decades.
Looking ahead, he envisions a model of care in which treatment is inherently more reliable and aligned with real-world conditions, reducing both the cognitive and emotional burden of disease management. "Our objective is to change the experience of living with diabetes at a fundamental level," he says. "Progress is measured not only in clinical outcomes, but in how well treatment integrates into daily life."
For Tu, this moment represents both continuity and momentum. "For decades, the field has operated within the constraints of insulin as it exists," he reflects. "We now have the opportunity to redefine those constraints and transform the foundation of diabetes care."
